{"organizations": [], "uuid": "9a03b4788f3c7684ba67b203e9e10c58a6131aa1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/10/16/zafgen-fda-idUSL3N12G3K620151016", "country": "US", "title": "Zafgen says FDA puts obesity drug trial on partial hold", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "Zafgen says FDA puts obesity drug trial on partial hold | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T14:40:00.000+03:00", "replies_count": 0, "uuid": "9a03b4788f3c7684ba67b203e9e10c58a6131aa1"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/10/16/zafgen-fda-idUSL3N12G3K620151016", "ord_in_thread": 0, "title": "Zafgen says FDA puts obesity drug trial on partial hold", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Oct 16 Drug developer Zafgen Inc said the U.S. Food and Drug Administration had put a late-stage trial of its obesity drug on partial hold after a patient died during the study.\nA partial clinical hold is an order that the FDA issues to delay or suspend part of a company's clinical study. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)", "external_links": [], "published": "2015-10-16T14:40:00.000+03:00", "crawled": "2015-10-16T13:50:45.301+03:00", "highlightTitle": ""}